

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal619lxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files  
NEWS 3 Feb 06 Engineering Information Encompass files have new names  
NEWS 4 Feb 16 TOXLINE no longer being updated  
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure  
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA  
NEWS 7 May 07 DGENE Reload  
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL  
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's  
DWPI and DPCI  
NEWS 10 Aug 23 In-process records and more frequent updates now in  
MEDLINE  
NEWS 11 Aug 23 PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA  
NEWS 12 Aug 23 Adis Newsletters (ADISNEWS) now available on STN  
NEWS 13 Sep 17 IMSworld Pharmaceutical Company Directory name change  
to PHARMASEARCH  
  
NEWS EXPRESS August 15 CURRENT WINDOWS VERSION IS V6.0c,  
CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),  
AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:56:18 ON 24 SEP 2001

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 14:56:28 ON 24 SEP 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 23 SEP 2001 HIGHEST RN 358331-51-8  
DICTIONARY FILE UPDATES: 23 SEP 2001 HIGHEST RN 358331-51-8

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
for details.

```
=> s soya peptide
      652 SOYA
      57495 PEPTIDE
L1      0. SOYA PEPTIDE
          (SOYA(W) PEPTIDE)
```

```
=> s phytokine
L2      1 PHYTOKINE
```

```
=> s kollaren ccp
      1 KOLLAREN
      40 CCP
L3      0 KOLLAREN CCP
          (KOLLAREN(W) CCP)
```

=> fil caplus uspatfull embase kosmet biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	19.93	20.08

FILE 'CAPLUS' ENTERED AT 14:58:09 ON 24 SEP 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:58:09 ON 24 SEP 2001  
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 14:58:09 ON 24 SEP 2001  
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'KOSMET' ENTERED AT 14:58:09 ON 24 SEP 2001  
COPYRIGHT (C) 2001 International Federation of the Societies of Cosmetics  
Chemists

FILE 'BIOSIS' ENTERED AT 14:58:09 ON 24 SEP 2001  
COPYRIGHT (C) 2001 BIOSIS(R)

```
=> fil l2 or soya peptide or kollaren ccp
'L2' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):end
```

```
=> 2 l2 or soya peptide or kollaren ccp.
```

2 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s l2 or soya peptide or kollaren ccp  
L4 13 L2 OR SOYA PEPTIDE OR KOLLAREN CCP

=> dup rem l4  
DUPLICATE IS NOT AVAILABLE IN 'KOSMET'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING COMPLETED FOR L4  
L5 11 DUP REM L4 (2 DUPLICATES REMOVED)

=> d ibib abs

L5 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 2000:240911 CAPLUS  
DOCUMENT NUMBER: 132:269849  
TITLE: Cosmetic composition comprising anti-striae peptides  
for the prevention and/or treatment of skin striae  
INVENTOR(S): Msika, Philippe  
PATENT ASSIGNEE(S): Laboratoires Pharmascience, Fr.  
SOURCE: PCT Int. Appl., 30 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000019974	A1	20000413	WO 1999-FR2375	19991005
W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
FR 2784029	A1	20000407	FR 1998-12435	19981005
FR 2784029	B1	20010105		
AU 9959894	A1	20000426	AU 1999-59894	19991005
PRIORITY APPLN. INFO.:			FR 1998-12435 A	19981005
			WO 1999-FR2375 W	19991005

AB The invention concerns a method for prevention and/or cosmetic treatment of skin striae, characterized in that it consists in applying on the zones likely to form or already affected by striae a compn. comprising, in an appropriate excipient, at least an anti-striae agent selected among the group consisting of soya bean peptides, tripeptides formed with glycine, histidine and lysine amino acids, and the mixts. thereof. The invention concerns the use of said compn. in dermatol. It enables to prevent and/or treat skin striae efficiently and is acceptable as far as skin tolerance is concerned. An anti-striae cream contained cetyl dimethicone 2, octyl sebacate 5, isononyl isononanoate 7, Cutina CBS 2.5, Me paraben 0.1, Pr paraben 0.1, PEG-300 5, triethanolamine 4.8, Sepigel-305 5.5, Phytokine 2,

lactic acid 10, Enteline-2 0.4, sophora japonica 3, methylsilanol lactate 3, zinc gluconate 0.2, copper gluconate 0.2, perfume 0.35, and water q.s. 100%. Efficacy of the compn. in the treatment of skin striae was shown.

REFERENCE COUNT: 2  
REFERENCE(S): (1) Moy, L; US 5759555 A 1998 CAPLUS  
(2) Rapaport, J; US 5444091 A 1995 CAPLUS

=> d 2 ibib abs

L5 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 2000:542381 CAPLUS  
DOCUMENT NUMBER: 133:136817  
TITLE: Surface treated inorganic or organic powders  
INVENTOR(S): Hyodo, Shoji  
PATENT ASSIGNEE(S): Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000219820	A2	20000808	JP 1999-59167	19990129

AB The surfaces of (in)org. powders having a diam. of 0.01-50 .mu.m are treated with 0.1-5.0% polypeptide (derivs.) to improve the dispersibility.  
Stirring 5 kg TiO2 powders at 3,000 rpm and spraying with a mixt. of 400-g water and 100-g **soya peptide**, drying in vacuo, and pulverizing gave powders easily dispersed in polar solvent and/or org. solvent-based matrix.

=> d 3 ibib abs

L5 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1999:244556 CAPLUS  
DOCUMENT NUMBER: 130:301685  
TITLE: Peptide/lipid complex formation by co-lyophilization  
INVENTOR(S): Dasseux, Jean-Louis  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 42 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9917740	A1	19990415	WO 1998-US20330	19980928

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6287590 B1 20010911 US 1997-942597 19971002  
 AU 9896715 A1 19990427 AU 1998-96715 19980928  
 EP 1019025 A1 20000719 EP 1998-950743 19980928

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, FI

NO 2000001683 A 20000510 NO 2000-1683 20000331

PRIORITY APPLN. INFO.: US 1997-942597 A 19971002  
 WO 1998-US20330 W 19980928

AB The invention relates to the formation of peptide/lipid vesicles and  
 complexes through the co-lyophilization of peptides, preferably that are  
 able to adopt an amphipathic .alpha.-helical conformation, and one or  
 more lipids. A single soln. which solubilizes both the peptides and lipids or  
 two sep. solns. may be lyophilized. The methods are used to generate  
 stable peptide/lipid vesicles and complexes including micellar,  
 spherical,  
 and discoidal complexes in bulk preps. and in smaller units, as may be  
 suitable for dosage forms. Peptide 1 (PVLDLFRELLNELLEALKQKLLK) was  
 dissolved in methanol at a concn. of 3.5 mg/mL by incubation for several  
 mins. and mixing by vortex intermittently. To this soln. was added  
 dipalmitoylphosphatidylcholine (DPPC) in methanol (100 mg/mL) such that  
 the final ratio of DPPC/peptide was 2.5:1. Xylene was added to the soln.  
 to a final concn. of 36 %. The soln. was freeze-dried and an aliquot  
 contg. 20 mg peptide 1 and 50 mg DPPC was rehydrated in a saline soln.,  
 mixed, and heated to 41.degree. until a clear soln. of reconstituted  
 peptide/phospholipid complexes resulted.

REFERENCE COUNT: 2

REFERENCE(S): (1) Lerch; US 5652339 A 1997 CAPLUS  
 (2) Nedelec, J; Biochimie 1989, V71, P145 CAPLUS

=> d 4 ibib abs

L5 ANSWER 4 OF 11 USPATFULL

ACCESSION NUMBER: 1998:17293 USPATFULL

TITLE: Derivative of caffeic acid, oraposide, and cosmetic or  
 pharmaceutical compositions, in particular  
 dermatological compositions, containing it

INVENTOR(S): Andary, Claude, Montpellier Cedex, France  
 Andre, Patrice, Neuville aux Bois, France

PATENT ASSIGNEE(S): Parfums Christian Dior, Paris, France (non-U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5719129		19980217
	WO 9216544		19921001
APPLICATION INFO.:	US 1993-119172		19931015 (8)
	WO 1991-FR229		19910321
			19931015 PCT 371 date
			19931015 PCT 102(e) date
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Peselev, Elli		
LEGAL REPRESENTATIVE:	Foley & Lardner		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 2 Drawing Page(s)		

LINE COUNT: 713

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a new derivative of caffeic acid.

This new derivative has the formula I below: ##STR1## in which one or more R independently represent a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, in particular methyl, and an acyl group, in particular a C.sub.1 -C.sub.6 group, in particular acetyl.

This new derivative called oraposide is particularly useful for the preparation of cosmetic or pharmaceutical compositions, in particular dermatological compositions, as a result in particular of its activity against free radicals, inflammation and aging due to radiation exposure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 5 ibib abs

L5 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1

ACCESSION NUMBER: 1998:390763 CAPLUS

DOCUMENT NUMBER: 129:173454

TITLE: Activation of fibroblast metabolism in a dermal and skin equivalent model: a screening test for activity of peptides

AUTHOR(S): Frei, V.; Perrier, E.; Orly, I.; Huc, A.; Augustin, C.; Damour, O.

CORPORATE SOURCE: COLETICA, Lyon, Fr.

SOURCE: Int. J. Cosmet. Sci. (1998), 20(3), 159-173

CODEN: IJCMDW; ISSN: 0142-5463

PUBLISHER: Chapman & Hall

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Skin firmness, elasticity and tone are gradually lost with age. These changes originate in the dermis and correspond to a decrease in the ability of cells, particularly the fibroblasts, to regenerate the mols. which make up the extracellular matrix. Skin aging is also characterized by a redn. of the epidermal thickness and by a flattening of the basal membrane. The recent development of two 3-dimensional culture systems,

in which the cells develop within a porous structure reproducing the extracellular matrix of the human dermis, is a way of reproducing in vivo conditions and demonstrating the biol. effects of anti-aging compds. The dermal equiv. model used in this study is composed of a dermal matrix

made of collagen-chitosan-glycosaminoglycans populated by normal human fibroblasts which synthesized their own extracellular matrix. A skin equiv. model is obtained by the cell culture of normal human

keratinocytes

onto a dermal equiv. elevated at the air-liq. interface. Such models were

used to prove anti-ageing activity of promising compds. Cosmetic science has used many protein hydrolyzates in order to fight skin ageing, but up to now, these natural peptides were poorly studied, and their efficacy poorly demonstrated. Eight protein hydrolyzates were screened in a proliferation study in monolayered cultures giving two selected polypeptides. A soya derived peptide was used for an efficiency study in 3-dimensional models. In the dermal equiv. model, this peptide increased

fibroblast proliferation by 40% and led to a stimulation of collagen formation (+65%) and elastin (+16%) synthesis. The effect of this **soya peptide** on glycosaminoglycan synthesis was also significant, with increases of 36% for chondroitin-4-sulfate and 68% for hyaluronic acid. These results were confirmed using a skin equiv. model. In this model, the **soya peptide** increased the thickness of the epidermis.

=> d 5 kwic

L5 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1  
 AB . . . proliferation by 40% and led to a stimulation of collagen formation (+65%) and elastin (+16%) synthesis. The effect of this **soya peptide** on glycosaminoglycan synthesis was also significant, with increases of 36% for chondroitin-4-sulfate and 68% for hyaluronic acid. These results were confirmed using a skin equiv. model. In this model, the **soya peptide** increased the thickness of the epidermis.

=> d 6 ibib abs

L5 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 1997:630750 CAPLUS  
 DOCUMENT NUMBER: 127:326571  
 TITLE: Anti-alopecia agents  
 INVENTOR(S): Yoshikawa, Masaaki; Takahata, Chikanari; Takatsuji, Masao; Yamada, Tadakazu  
 PATENT ASSIGNEE(S): Honen Corp., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09249535	A2	19970922	JP 1996-84667	19960313

AB Anti-alopecia agents contain soya peptides i.e. Met-Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn-Lys-Pro-Gly-Arg, Met-Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn-Lys-Pro-Gly, Met-Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn-Lys-Pro, Met-Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn-Lys, Met-Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn, Met-Ile-Thr-Leu-Ala-Ile-Pro-Val, Met-Ile-Thr-Leu-Ala-Ile-Pro, Met-Ile-Thr-Leu-Ala-Ile, Met-Ile-Thr-Leu-Ala, Met-Ile-Thr-Leu-Ala, and/or Met-Ile-Thr-Leu. The soya peptides can be incorporated into injections or other drug delivery systems. Effectiveness was tested in an exptl..male rat model.

=> d 7 ibib abs

L5 ANSWER 7 OF 11 USPATFULL  
 ACCESSION NUMBER: 97:24738 USPATFULL  
 TITLE: Cosmetic composition for the simultaneous treatment of the surface and deep layers of the skin, its use  
 INVENTOR(S): Ribier, Alain, Paris, France  
 Simonnet, Jean-Thierry, Paris, France

PATENT ASSIGNEE(S): L'Oreal, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5614215		19970325
APPLICATION INFO.:	US 1994-366723		19941230 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1993-15863	19931230
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	645	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition comprising a first dispersion of lipid vesicles capable of

entering the deep layers of the skin and containing at least one first active substance capable of treating these deep layers, and a second dispersion of lipid vesicles capable of entering the surface layers of the skin and containing at least one second active substance, different from the first active substance, capable of treating these surface layers is found effective for anti-age, anti-wrinkle, depigmenting, nutrient, slimming, hydrating, anti-ache, antimycotic, anti-dermic and anti-psoriatic treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 8 ibib abs

L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1992:549463 CAPLUS  
DOCUMENT NUMBER: 117:149463  
TITLE: Manufacture of peptide mixtures and beverages containing them  
INVENTOR(S): Kimoto, Minoru; Matsui, Masayuki; Nakamori, Toshihiro;  
Matsuo, Takaaki  
PATENT ASSIGNEE(S): Fuji Oil Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 04190797	A2	19920709	JP 1990-326585	19901127
AB	Peptide mixts. are manufd. by (i) centrifuging hydrolyzate (obtained by enzymic decompn. of vegetable proteins with endoprotease) in acidic water system to remove ppt. and (ii) subsequently treating with anion-exchange resins. Beverages contg. 0.1-50 wt.% peptide mixts have good flavor, are ppt.-free, and do not discolor. Thus, 10% aq. soln. (pH 7) of 1 kg Fujipro R (sepd. soybean protein) was hydrolyzed with Protin AC-10 (endoprotease) at 50.degree. for 5 h, then the enzyme was inactivated.				



The pH was adjusted to 4.0 and the soln. was centrifuged to remove the ppt., which (50 kg) was treated with KA-890 (weakly basic anion-exchange resin) and filtered to give a soln. The soln. (10 kg) was treated with HP-20 (hydrophobic adsorbent), filtered, and dried to give 210 g peptide mixt. The peptide mixt. 20, sucrose 60, and citric acid 1.2 g were mixed to adjust the pH to 3.8, and further mixed with orange, lemon, and pineapple flavors to give a beverage.

=> d 8 kwic

L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2001 ACS  
IT Protein hydrolyzates  
RL: BIOL (Biological study)  
(soya, peptide mixts. manuf. from, with  
endoprotease, for beverage manuf.)

=> d 9 ibib abs

L5 ANSWER 9 OF 11 USPATFULL  
ACCESSION NUMBER: 78:784 USPATFULL  
TITLE: Process for extracting a polypeptide from an aqueous  
solution  
INVENTOR(S): Schneider, Michel, Grand-Lancy, Switzerland  
PATENT ASSIGNEE(S): Battelle Memorial Institute, Switzerland (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4066505		19780103
APPLICATION INFO.:	US 1976-667258		19760316 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1975-3468	19750318
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shapiro, Lionel M.	
LEGAL REPRESENTATIVE:	Burns, Robert E., Lobato, Emmanuel J., Adams, Bruce L.	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	418	

AB A polypeptide is extracted from an aqueous solution by a process in which a water-soluble macromolecular complex (I) of macromolecules covalently bonded to molecules of at least one compound capable of fixing the polypeptide in a selective, reversible and non-destructive manner, is selectively reacted with the polypeptide in the solution to fix the polypeptide by forming in solution a complex (II); and the complex (II) is separated from the solution and dissociated into polypeptide molecules and complex (I) molecules, and the polypeptide is isolated.

=> d 9 kwic

L5 ANSWER 9 OF 11 USPATFULL  
CLM What is claimed is:  
. . . in which the said molecules are molecules selected from the group

comprising p-aminobenzoic acid, o-aminobenzoic acid, trypsin, N-.omega.-aminohexyl-L-aspartic acid, trypsin-inhibiting **soya peptide**, p-aminophenyl-thiogalactoside, poly-L-lysine, nicotinamide adenine dinucleotide (NAD) and D-asparagine.

=> d 10 ibib abs

L5 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1979:20965 CAPLUS

DOCUMENT NUMBER: 90:20965

TITLE: The determination of soya protein in meat products using peptide analysis and the characterization of the

specific **soya peptide** used in the calculations

AUTHOR(S): Bailey, Frank J.; Llewellyn, Jeffery W.; Hitchcock, Christopher H. S.; Dean, Ann C.

CORPORATE SOURCE: Unilever Res. Lab., Sharnbrook, Engl.

SOURCE: Chem. Ind. (London) (1978), (13), 477-8

CODEN: CHINAG; ISSN: 0009-3068

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The structure of SP-1, the soya-specific peptide used in the title anal., and the protein source in the soya were detd. for digests of 3 main soya protein fractions by ion-exchange chromatog. The SP-1 peaks were heterogeneous, consisting of one main component and .gtoreq.7 minor ones and the cor. amino acid values matched a peptide contg. 1 serine residue, 2 glutamic acid residues, 1 alanine, and 1 arginine residue. The results were consistent with those obtained using known anal. techniques and showed that the arginine peptide was the main component of SP-1 and it originated from the 11S protein fraction of soya bean.

=> d 11 ibib abs

L5 ANSWER 11 OF 11 KOSMET COPYRIGHT 2001 IFSCC

ACCESSION NUMBER: 20509 KOSMET

FILE SEGMENT: scientific, technical

TITLE: ACTIVATION OF FIBROBLAST METABOLISM IN A DERMAL AND SKIN EQUIVALENT MODEL: A SCREENING TEST FOR ACTIVITY OF PEPTIDES

AUTHOR: FREI V (COLETICA, 32, RUE SAINT JEAN DE DIEU, LYON, FRANCE); PERRIER E; ORLY I; HUC A; AUGUSTIN C; DAMOUR O

SOURCE: PRESENTED AT THE 19TH IFSCC CONGRESS IN SYDNEY, 22-25 OCTOBER 1996, INT J.COSMET SCI, 1998, 20, 3, 159-173, 26 REFS

LANGUAGE: English

AN 20509 KOSMET FS scientific, technical

AB Skin firmness, elasticity and tone are gradually lost with age. These changes originate in the dermis and correspond to a decrease in the ability of cells, particularly the fibroblasts, to regenerate the molecules which make up the extracellular matrix. Skin ageing is also characterized by a reduction of the epidermal thickness and by a flattening of the basal membrane. The recent development of two 3-dimensional culture systems, in which the cells develop within a

porous structure reproducing the extracellular matrix of the human dermis, is a

way of reproducing in vivo conditions and demonstrating the biological effects of anti-ageing compounds. The dermal equivalent model used in this study is composed of a dermal matrix made of collagen-chitosan-glycosaminoglycans populated by normal human fibroblasts which synthesized their own extracellular matrix. A skin equivalent model is obtained by the cell culture of normal human keratinocytes onto a dermal equivalent elevated at the air-liquid interface. Such models were used to prove anti-ageing activity of promising compounds. Cosmetic Science has used many protein hydrolysates in order to fight skin ageing, but up to now, these natural peptides were poorly studied, and their efficacy poorly demonstrated. Eight protein hydrolysates were screened in a proliferation study in monolayered cultures giving two selected polypeptides. A soya derived peptide was used for an efficiency study in 3-dimensional models. In the dermal equivalent model, this peptide increased fibroblast proliferation by 40% and led to a stimulation of collagen formation (+65%) and elastin (+16%) synthesis. The effect of this **soya peptide** on glycosaminoglycan synthesis was also significant, with increases of 36% for chondroitin-4-sulfate and 68% for hyaluronic acid. These results were confirmed using a skin equivalent model. In this model, the **soya peptide** increased the thickness of the epidermis

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	37.24	57.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.70	-4.70

\* \* \* \* \*

Dear valued customer,

Your feedback is important to us. Would you kindly take a moment to complete our survey? This survey will only take about 5-10 minutes to complete. Your responses will be kept confidential and will help us improve STN Express with Discover! for your future use. Please click on the following link to access the survey.

<http://www.cas.org/ONLINE/STN/ExpressSurveyForm.html?LOGINID=SSSPTA1619LXW>

\* \* \* \* \*

STN INTERNATIONAL LOGOFF AT 15:05:44 ON 24 SEP 2001

**WEST****Freeform Search**

<b>Database:</b>	US Patents Full-Text Database ▲				
	US Pre-Grant Publication Full-Text Database				
	JPO Abstracts Database				
	EPO Abstracts Database				
	Derwent World Patents Index				
	IBM Technical Disclosure Bulletins ▼				
<b>Term:</b>	enteromorpha compressa or chlorophyceae or enteline				
	2				
<b>Display:</b>	10	<b>Documents in Display Format:</b>	CIT	<b>Starting with Number</b>	1
<b>Generate:</b>	<input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Image				

Search	Clear	Help	Logout	Interrupt
--------	-------	------	--------	-----------

Main Menu	Show S Numbers	Edit S Numbers	Preferences
-----------	----------------	----------------	-------------

---

**Search History**

---

**Today's Date: 9/24/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,DWPI	l30 and l17	0	<a href="#">L31</a>
USPT,PGPB,DWPI	l6 and l7	131	<a href="#">L30</a>
USPT,PGPB,DWPI	l10 and l18	0	<a href="#">L29</a>
USPT,PGPB,DWPI	l10 and l17	0	<a href="#">L28</a>
USPT,PGPB,DWPI	l10 and l16	0	<a href="#">L27</a>
USPT,PGPB,DWPI	l10 and l15	0	<a href="#">L26</a>
USPT,PGPB,DWPI	l10 and l15 and l16	0	<a href="#">L25</a>
USPT,PGPB,DWPI	l22 and l16	0	<a href="#">L24</a>
USPT,PGPB,DWPI	l22 and l15	0	<a href="#">L23</a>
USPT,PGPB,DWPI	l10 and l14	26	<a href="#">L22</a>
USPT,PGPB,DWPI	l10 and l13	49	<a href="#">L21</a>
USPT,PGPB,DWPI	l18 and l16 and l15 and l13	3	<a href="#">L20</a>
USPT,PGPB,DWPI	l18 and l16 and l15 and l13	3	<a href="#">L19</a>
USPT,PGPB,DWPI	sophora japonica or methylsilaryl lactate or copper gluconate or zinc gluconate	630	<a href="#">L18</a>
USPT,PGPB,DWPI	enteromorpha compressa or chlorophycea or enteline 2	10	<a href="#">L17</a>
USPT,PGPB,DWPI	neuropeptide y or neuropeptide-y	638	<a href="#">L16</a>
USPT,PGPB,DWPI	substance p or substance-p	2855	<a href="#">L15</a>
USPT,PGPB,DWPI	lactic acid	33291	<a href="#">L14</a>
USPT,PGPB,DWPI	alpha hydroxy acid or citric or pyruvic or glycolic or lactic	107663	<a href="#">L13</a>
USPT,PGPB,DWPI	(tripeptide) and (glycine near histidine near lysine)	12	<a href="#">L12</a>
USPT,PGPB,DWPI	soya peptide or phytokine or kollaren cpp or kollaren-cpp	4	<a href="#">L11</a>
USPT,PGPB,DWPI	stretchmark or stretch mark	222	<a href="#">L10</a>
USPT	sophora japonica or methylsilaryl lactate or copper gluconate or zinc gluconate	457	<a href="#">L9</a>
USPT	enteromorpha compressa or chlorophycea or enteline 2	5	<a href="#">L8</a>
USPT	neuropeptide y or neuropeptide-y	455	<a href="#">L7</a>
USPT	substance p or substance-p	2213	<a href="#">L6</a>
USPT	lactic acid	24925	<a href="#">L5</a>
USPT	alpha hydroxy acid or citric or pyruvic or glycolic or lactic	81413	<a href="#">L4</a>
USPT	(tripeptide) and (glycine near histidine near lysine)	10	<a href="#">L3</a>
USPT	soya peptide or phytokine or kollaren cpp or kollaren-cpp	3	<a href="#">L2</a>
USPT	stretchmark or stretch mark	148	<a href="#">L1</a>

**WEST**☐ Generate Collection

L17: Entry 8 of 10

File: DWPI

Jan 25, 1980

DERWENT-ACC-NO: 1980-16935C

DERWENT-WEEK: 198010

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Culture of phytoplankton in sea water - enriched with minerals, vitamin(s) and aminoacid(s), used in cosmetics and in human and veterinary medicine

INVENTOR: BREVIEW, J

PATENT-ASSIGNEE:

ASSIGNEE

CODE

BREVIEW J

BREVI

PRIORITY-DATA: 1978FR-0015678 (May 26, 1978)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
FR 2426404 A	January 25, 1980	N/A	000	N/A

INT-CL (IPC): A01G 33/02; A23K 1/18

ABSTRACTED-PUB-NO: FR 2426404A

BASIC-ABSTRACT:

Phytoplankton of the unicellular flagellate algae family chlorophyceae, esp. chlorella SP is cultivated in a process in which sea-water is enriched with minerals, vitamins, and amino acids, seeded with the phytoplankton, and kept under proper conditions of temp., aeration and light for development. The culture is then successively transplanted after development.

In the first phase; culture is effected in a 500 ml. Erlenmeyer flask, and when the concn. of cells reaches 4 million/ml. it is passed to the second stage. This takes place in a 5 litre vessel. Illumination may be continuous or discontinuous and the temp. is kept at around 20 degrees C. When the flask contents reach satn. point, as far as phytoplankton development is concerned, which usually takes about 5 days, the culture may be continued in a larger vessel.

TITLE-TERMS: CULTURE PHYTOPLANKTON SEA WATER ENRICH MINERAL VITAMIN AMINOACID  
COSMETIC HUMAN VETERINARY MEDICINE

DERWENT-CLASS: B04 C03 D16 D21 P13

CPI-CODES: B04-B02B; B11-A; C04-B02B; C11-A; D05-H01; D08-B;

CHEMICAL-CODES:

Chemical Indexing M1 \*01\*

Fragmentation Code

V500 V550 N130 M720 M423 M902

Chemical Indexing M1 \*02\*

Fragmentation Code

V500 V550 N130 M720 M423 M902

